Precigen (PGEN) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.08
- Estimate
- $0.08
- Surprise
- +1.5%
- Revenue (period 2026-09-30)
- $74.1M
- Score at report (before → after)
- 4.1 → 4.1/10
Revenue source: xbrl.
How the report landed
Precigen (PGEN) reported adjusted EPS of $0.08, in line with the $0.08 estimate. TrendMatrix's engine moved from Sell (4.1/10) to Hold at 4.1/10 after the report.
Coverage in the report window
- Citizens Raises Precigen Price Target Following Q3 Results — fiscal.ai, 2026-11-06
- Citizens Maintains Market Outperform on Precigen, Raises Price Target to $12 — benzinga, 2026-11-05
- Precigen Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-04
Where TrendMatrix's rating stands now
TrendMatrix currently rates PGEN Hold at 4.4/10.
3 of the last 4 quarters beat the estimate; this quarter's +1.5% surprise compares with a +153.7% four-quarter average. Next scheduled report: 2027-03-24.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Concentration risk — Product: Papzimeos
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0)
- Leverage penalty (D/E 2.3): -1.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.21
- Price target
- $7.71
- Stop
- $3.91
- Upside to target
- +83.4%
Risk check: RSI 25 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
PGEN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.50B
- P/E (fwd)
- -19.2
- P/E (ttm)
- 38.4
- 52-week range
- $3.04–$8.98
- Off 52-week high
- 53.2%
- RSI (14)
- 25
- Volume vs avg
- 0.47×
- Score today
- 4.4/10